BET inhibitor Pelabresib and AR inhibitor enzalutamide perturbed pathways in prostate cancer CRPC PDX LuCaP 35CR

To study the effect of inhibiting AR and HNF1A/HNF4G activity either alone or in combination on the growth of CRPC PDX LuCaP 35CR LuCaP 35CR tumors were treated with enzalutamide, pelabresib or a combination of pelabresib and enzalutamide and tumor volumes were compared to vehicle control

为探究单独或联合抑制AR（Androgen Receptor）与HNF1A/HNF4G（Hepatocyte Nuclear Factor 1A/Hepatocyte Nuclear Factor 4G）的活性对去势抵抗性前列腺癌（Castration-Resistant Prostate Cancer, CRPC）患者来源异种移植瘤（Patient-Derived Xenograft, PDX）LuCaP 35CR的生长影响，本实验对LuCaP 35CR肿瘤分别施以恩扎卢胺（Enzalutamide）、帕拉瑞塞布（Pelabresib），或二者联合处理，并将各组肿瘤体积与溶剂对照组进行对比。